We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$10.2B
AUM Growth
+$793M
Cap. Flow
+$230M
Cap. Flow %
2.25%
Top 10 Hldgs %
30.33%
Holding
229
New
13
Increased
77
Reduced
41
Closed
15

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$74.7M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$44M
3
IQV icon
IQVIA
IQV
+$40.5M
4
MGNX icon
MacroGenics
MGNX
+$39.5M
5
SAGE
Sage Therapeutics
SAGE
+$39.1M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$222M
2
MRNA icon
Moderna
MRNA
+$47.8M
3
CI icon
Cigna
CI
+$47.8M
4
BMY icon
Bristol-Myers Squibb
BMY
+$40.5M
5
DVA icon
DaVita
DVA
+$39.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.41%
2 Industrials 0.94%
3 Technology 0.31%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$24.5B
$597M 5.83%
2,542,300
-267,650
-10% -$47.8M
IONS icon
2
Ionis Pharmaceuticals
IONS
$8.99B
$396M 3.87%
9,930,245
+946,011
+11% +$37.1M
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$123B
$350M 3.41%
1,733,694
+356,990
+26% +$74.7M
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$294M 2.87%
3,017,751
-256,800
-8% -$24.6M
ARGX icon
5
argenx
ARGX
$53.8B
$293M 2.86%
974,038
+19,484
+2% +$5.54M
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$35.7B
$263M 2.56%
1,549,092
-78,022
-5% -$11.4M
INCY icon
7
Incyte
INCY
$23.4B
$250M 2.44%
2,971,400
-34,300
-1% -$2.86M
AGIO icon
8
Agios Pharmaceuticals
AGIO
$2.36B
$240M 2.34%
4,352,992
-184,100
-4% -$10.3M
FATE icon
9
Fate Therapeutics
FATE
$324M
$227M 2.21%
2,613,536
+404,200
+18% +$32.6M
MGNX icon
10
MacroGenics
MGNX
$285M
$198M 1.93%
7,376,026
+1,348,100
+22% +$39.5M
ISRG icon
11
Intuitive Surgical
ISRG
$122B
$186M 1.81%
606,285
-56,040
-8% -$15.7M
BIIB icon
12
Biogen
BIIB
$30.4B
$183M 1.79%
528,100
-30,300
-5% -$9.18M
ELV icon
13
Elevance Health
ELV
$80.9B
$178M 1.74%
465,976
+80,428
+21% +$30.7M
ARVN icon
14
Arvinas
ARVN
$517M
$172M 1.68%
2,237,403
+165,900
+8% +$11.5M
ABT icon
15
Abbott
ABT
$175B
$160M 1.56%
1,377,499
-15,500
-1% -$1.81M
CRSP icon
16
CRISPR Therapeutics
CRSP
$4.71B
$157M 1.53%
966,884
-11,500
-1% -$1.4M
ITCI
17
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$147M 1.44%
3,609,919
-50,000
-1% -$1.85M
RDUS
18
DELISTED
Radius Health, Inc.
RDUS
$137M 1.34%
7,531,414
– –
UNH icon
19
UnitedHealth
UNH
$387B
$137M 1.34%
343,051
-14,330
-4% -$5.71M
SAGE
20
DELISTED
Sage Therapeutics
SAGE
$134M 1.31%
2,364,204
+553,500
+31% +$39.1M
DHR icon
21
Danaher
DHR
$144B
$130M 1.27%
544,756
+11,054
+2% +$2.45M
HUM icon
22
Humana
HUM
$48B
$125M 1.22%
282,755
-5,964
-2% -$2.61M
MYOV
23
DELISTED
Myovant Sciences Ltd.
MYOV
$120M 1.17%
5,269,039
+75,000
+1% +$1.58M
BDX icon
24
Becton Dickinson
BDX
$43.6B
$112M 1.09%
472,489
– –
AXNX
25
DELISTED
Axonics, Inc. Common Stock
AXNX
$110M 1.07%
1,730,471
+274,197
+19% +$16.2M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2021 Portfolio in Review

As of Q2 2021, Bellevue Group held 229 positions worth $10.2B, up 8.4% from $9.45B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q2 2021 filing shows 13 new, 77 increased, 41 reduced and 15 closed positions. Its largest new stake was Adaptive Biotechnologies: 962,352 shares worth $39.3M. The largest sale was Alexion Pharmaceuticals, an estimated $222M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2021 buy was Adaptive Biotechnologies: 962,352 shares worth $39.3M.
  • Bellevue Group added most to Vertex Pharmaceuticals in Q2 2021, an estimated $74.7M increase.
  • Bellevue Group's biggest Q2 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $222M.
  • Bellevue Group fully exited DaVita in Q2 2021, selling an estimated $39.6M.
  • Bellevue Group's ten largest holdings make up 30% of its $10.2B portfolio in Q2 2021.
  • Bellevue Group opened 13 new positions and closed 15 in Q2 2021.
  • Bellevue Group's portfolio value rose 8.4% quarter-over-quarter to $10.2B.

Based on Bellevue Group's 13F filing for Q2 2021, filed 12 Aug 2021.